Dazucorilant

Corcept Therapeutics has submitted a New Drug Application to the FDA for relacorilant, a selective cortisol modulator designed to treat patients with endogenous hypercortisolism (Cushing's syndrome).

Corcept Therapeutics' dazucorilant did not meet the primary endpoint in the DAZALS Phase 2 trial for amyotrophic lateral sclerosis (ALS).

Corcept Therapeutics' GRADIENT trial demonstrates relacorilant's efficacy in treating Cushing's syndrome, showing clinically meaningful improvements in hypercortisolism signs and symptoms.

The MIROCALS trial testing low-dose interleukin-2 (IL-2) for motor neurone disease (MND) failed to meet its primary endpoint for the overall population, with results published in The Lancet on May 9, 2025.